Liquidia Corporation (LQDA)Healthcare | Drug Manufacturers - Specialty & Generic | Morrisville, United States | NasdaqCM
39.47 USD
-1.93
(-4.662%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 39.08 -0.39 (-0.390%) ⇩ (April 17, 2026, 7:21 p.m. EDT) Short-term: ★★★☆☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:55 a.m. EDT
The 135% surge is technically confirmed by the 52-week high breach, but the short-term outlook hinges on holding above the $40 volume wall. While fundamental inflows (revenue growth +5, pipeline hurdles cleared) look positive long-term, the valuation is extremely stretched (P/S ~22x vs negative earnings) and insider selling of ~$4M is a significant overhang. Technically, the stock is in a bullish channel but faces heavy decimal resistance. Neutral to bullish near-term if volume sustains, but high risk/reward given the insider selling and fundamental lag time. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.091820 |
| MSTL | 0.106776 |
| AutoTheta | 0.242930 |
| AutoARIMA | 0.336122 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.61 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.833 |
| Excess Kurtosis | -0.38 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 442.315 |
| Revenue per Share | 1.84 |
| Market Cap | 3,477,876,736 |
| Forward P/E | 7.54 |
| Beta | 0.46 |
| Profit Margins | -43.54% |
| Previous Name | Liquidia Technologies, Inc. |
| Website | https://www.liquidia.com |
As of April 19, 2026, 12:55 a.m. EDT: Dealer positioning is heavily skewed towards being short gamma above the current price (approx $39.50-S$40). The 2026-04-17 data shows massive Call OI (10k+) and Put OI (32k) at strikes just above current value, while Put OI ('Major OI Wall') is heaviest at deep OTM strikes ($20, $30). This creates a synthetic short barrier; for the price to move up, speculation must exceed dealer limits. The volatility skew shows severely depressed IV for OTM calls (implied ~2.92% vs ATM) relative to deep ITM premiums, suggesting the market is not fully pricing in the upside momentum seen in the recent 135% rally and patent news. Most medium-term (May) Call positioning is beyond $40, confirming a passive bullish bias.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.9699023 |
| Address1 | 419 Davis Drive |
| Address2 | Suite 100 |
| All Time High | 46.67 |
| All Time Low | 2.25 |
| Ask | 39.58 |
| Ask Size | 1 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.6 - Buy |
| Average Daily Volume10 Day | 1,173,290 |
| Average Daily Volume3 Month | 1,583,611 |
| Average Volume | 1,583,611 |
| Average Volume10Days | 1,173,290 |
| Beta | 0.457 |
| Bid | 39.36 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 0.513 |
| City | Morrisville |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 39.47 |
| Current Ratio | 2.014 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 41.95 |
| Day Low | 37.9 |
| Debt To Equity | 442.315 |
| Display Name | Liquidia |
| Earnings Call Timestamp End | 1,772,717,400 |
| Earnings Call Timestamp Start | 1,772,717,400 |
| Earnings Timestamp | 1,772,717,400 |
| Earnings Timestamp End | 1,778,157,000 |
| Earnings Timestamp Start | 1,778,157,000 |
| Ebitda | -50,348,000 |
| Ebitda Margins | -0.31801 |
| Enterprise To Ebitda | -69.221 |
| Enterprise To Revenue | 22.013 |
| Enterprise Value | 3,485,123,584 |
| Eps Current Year | 2.578 |
| Eps Forward | 5.238 |
| Eps Trailing Twelve Months | -0.8 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 919 328 4402 |
| Fifty Day Average | 36.7284 |
| Fifty Day Average Change | 2.7416 |
| Fifty Day Average Change Percent | 0.07464523 |
| Fifty Two Week Change Percent | 196.99023 |
| Fifty Two Week High | 46.67 |
| Fifty Two Week High Change | -7.199997 |
| Fifty Two Week High Change Percent | -0.15427464 |
| Fifty Two Week Low | 11.85 |
| Fifty Two Week Low Change | 27.62 |
| Fifty Two Week Low Change Percent | 2.3308017 |
| Fifty Two Week Range | 11.85 - 46.67 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,532,611,800,000 |
| Float Shares | 60,761,948 |
| Forward Eps | 5.238 |
| Forward P E | 7.5353193 |
| Free Cashflow | -43,121,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 216 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.91636 |
| Gross Profits | 145,078,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.13367 |
| Held Percent Institutions | 0.71062 |
| Implied Shares Outstanding | 88,114,429 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina. |
| Long Name | Liquidia Corporation |
| Market | us_market |
| Market Cap | 3,477,876,736 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_22761611 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-19 |
| Net Income To Common | -68,924,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,472,589,646 |
| Number Of Analyst Opinions | 9 |
| Open | 41.4 |
| Operating Cashflow | -35,686,000 |
| Operating Margins | 0.21503 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 919 328 4400 |
| Post Market Change | -0.3899994 |
| Post Market Change Percent | -0.98809063 |
| Post Market Price | 39.08 |
| Post Market Time | 1,776,468,066 |
| Prev Name | Liquidia Technologies, Inc. |
| Previous Close | 41.4 |
| Price Eps Current Year | 15.310318 |
| Price Hint | 2 |
| Price To Book | 76.939575 |
| Price To Sales Trailing12 Months | 21.967386 |
| Profit Margins | -0.43535 |
| Quick Ratio | 1.803 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.55556 |
| Region | US |
| Regular Market Change | -1.93 |
| Regular Market Change Percent | -4.66184 |
| Regular Market Day High | 41.95 |
| Regular Market Day Low | 37.9 |
| Regular Market Day Range | 37.9 - 41.95 |
| Regular Market Open | 41.4 |
| Regular Market Previous Close | 41.4 |
| Regular Market Price | 39.47 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 2,415,277 |
| Return On Assets | -0.11504 |
| Return On Equity | -1.11055 |
| Revenue Growth | 30.546 |
| Revenue Per Share | 1.84 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 88,114,429 |
| Shares Percent Shares Out | 0.1346 |
| Shares Short | 11,861,739 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 11,927,074 |
| Short Name | Liquidia Corporation |
| Short Percent Of Float | 0.1664 |
| Short Ratio | 8.75 |
| Source Interval | 15 |
| State | NC |
| Symbol | LQDA |
| Target High Price | 67.0 |
| Target Low Price | 19.0 |
| Target Mean Price | 50.66667 |
| Target Median Price | 54.0 |
| Total Cash | 190,680,000 |
| Total Cash Per Share | 2.164 |
| Total Debt | 197,927,008 |
| Total Revenue | 158,320,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.8 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 29.63645 |
| Two Hundred Day Average Change | 9.833551 |
| Two Hundred Day Average Change Percent | 0.33180597 |
| Type Disp | Equity |
| Volume | 2,415,277 |
| Website | https://www.liquidia.com |
| Zip | 27,560 |